Thomas J Kipps Selected Research

B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia)

1/2022	High expression level of ROR1 and ROR1-signaling associates with venetoclax resistance in chronic lymphocytic leukemia.
1/2022	Up to 8-year follow-up from RESONATE-2: first-line ibrutinib treatment for patients with chronic lymphocytic leukemia.
1/2022	Enduring undetectable MRD and updated outcomes in relapsed/refractory CLL after fixed-duration venetoclax-rituximab.
1/2022	Phase 1 TRANSCEND CLL 004 study of lisocabtagene maraleucel in patients with relapsed/refractory CLL or SLL.
1/2022	Up to 6.5 years (median 4 years) of follow-up of first-line ibrutinib in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma and high-risk genomic features: integrated analysis of two phase 3 studies.
1/2022	Ibrutinib plus Obinutuzumab as Frontline Therapy for Chronic Lymphocytic Leukemia Is Associated with a Lower Rate of Infusion-Related Reactions and with Sustained Remissions after Ibrutinib Discontinuation: A Single-Arm, Open-Label, Phase 1b/2 Clinical Trial NCT0231576.
12/2021	Longitudinal Single-Cell Dynamics of Chromatin Accessibility and Mitochondrial Mutations in Chronic Lymphocytic Leukemia Mirror Disease History.
12/2021	Ibrutinib Plus Venetoclax for First-Line Treatment of Chronic Lymphocytic Leukemia: Primary Analysis Results From the Minimal Residual Disease Cohort of the Randomized Phase II CAPTIVATE Study.
1/2021	Phase II study of acalabrutinib in ibrutinib-intolerant patients with relapsed/refractory chronic lymphocytic leukemia.
1/2021	Recurrent XPO1 mutations alter pathogenesis of chronic lymphocytic leukemia.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Thomas J Kipps Research Topics

Disease

173	B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia) 01/2022 - 03/2002
67	Neoplasms (Cancer) 10/2022 - 02/2002
56	Leukemia 11/2019 - 01/2002
22	Disease Progression 01/2022 - 12/2002
11	Residual Neoplasm 01/2022 - 01/2003
11	Lymphoma (Lymphomas) 01/2019 - 02/2002
7	Neutropenia 01/2021 - 12/2015
7	Breast Neoplasms (Breast Cancer) 01/2020 - 08/2011
7	Infections 06/2019 - 08/2002
6	Hematologic Neoplasms (Hematological Malignancy) 03/2022 - 08/2002
6	Diarrhea 01/2021 - 07/2014
5	Tumor Lysis Syndrome 01/2022 - 02/2017
5	Fatigue 12/2019 - 07/2014
5	Lymphadenopathy 11/2019 - 02/2007
4	Lymphocytosis 01/2019 - 09/2013
4	Neoplasm Metastasis (Metastasis) 01/2019 - 06/2013
4	Chromosome Aberrations (Chromosome Abnormalities) 07/2014 - 10/2009
3	Cough 01/2021 - 07/2014
3	Non-Hodgkin Lymphoma (Lymphosarcoma) 01/2021 - 07/2015
3	Nausea 12/2019 - 07/2014
3	Hemorrhage 01/2019 - 12/2015
3	B-Cell Lymphoma (Lymphoma, B Cell) 01/2016 - 07/2003
3	Trisomy (Trisomies) 06/2014 - 10/2009
3	Carcinogenesis 05/2010 - 03/2004
2	Anemia 01/2021 - 12/2015
2	Cytopenia 01/2021 - 01/2016
2	Hypertension (High Blood Pressure) 12/2019 - 01/2019
2	Atrial Fibrillation 12/2019 - 10/2017
2	Mantle-Cell Lymphoma (Lymphoma, Mantle Cell) 05/2018 - 10/2017
2	Lymphoid Leukemia 12/2015 - 07/2014
2	Prolymphocytic Leukemia 05/2015 - 01/2003

Drug/Important Bio-Agent (IBA)

31	Proteins (Proteins, Gene)FDA Link 04/2019 - 08/2002
30	ibrutinibIBA 01/2022 - 03/2014
24	Rituximab (Mabthera)FDA Link 01/2022 - 02/2002
18	venetoclaxIBA 01/2022 - 01/2016
18	MicroRNAs (MicroRNA)IBA 11/2018 - 08/2004
15	fludarabineIBA 11/2018 - 01/2003
12	Agammaglobulinaemia Tyrosine KinaseIBA 01/2022 - 03/2014
12	Immunoglobulins (Immunoglobulin)IBA 04/2015 - 12/2002
11	AntigensIBA 01/2014 - 01/2002
10	obinutuzumabIBA 01/2022 - 04/2015
10	Chlorambucil (Leukeran)FDA Link 01/2022 - 04/2015
10	Monoclonal AntibodiesIBA 01/2019 - 02/2002
9	ofatumumab FDA Link 01/2019 - 04/2010
9	Biomarkers (Surrogate Marker)IBA 01/2019 - 10/2009
9	cirmtuzumabIBA 01/2019 - 12/2014
8	Pharmaceutical PreparationsIBA 12/2019 - 02/2002
8	Immunoglobulin Heavy Chains (Immunoglobulin Heavy Chain)IBA 11/2019 - 08/2004
8	AntibodiesIBA 01/2019 - 09/2004
8	Alemtuzumab (Campath)FDA Link 06/2013 - 01/2003
6	Receptor Tyrosine Kinase-like Orphan ReceptorsIBA 10/2022 - 01/2012
6	LigandsIBA 10/2022 - 08/2002
6	Cyclophosphamide (Cytoxan)FDA LinkGeneric 11/2018 - 01/2003
5	idelalisibIBA 01/2019 - 03/2014
5	DNA (Deoxyribonucleic Acid)IBA 05/2016 - 05/2010
4	Bendamustine Hydrochloride FDA Link 01/2022 - 01/2017
4	Messenger RNA (mRNA)IBA 01/2022 - 09/2011
4	Phosphotransferases (Kinase)IBA 01/2020 - 03/2008
4	Biological ProductsIBA 11/2019 - 08/2004
4	ChemokinesIBA 01/2019 - 03/2002
4	CXCR4 Receptors (CXCR4 Receptor)IBA 01/2016 - 11/2003
4	Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA 01/2015 - 01/2011
4	Chemokine CXCL12IBA 07/2014 - 11/2003
4	Chemokine ReceptorsIBA 01/2014 - 03/2002
4	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 12/2013 - 08/2002
4	B-Cell Activating FactorIBA 11/2010 - 01/2005
3	Transcription Factors (Transcription Factor)IBA 01/2021 - 06/2003
3	CytokinesIBA 01/2020 - 01/2012
3	Tyrosine (L-Tyrosine)FDA Link 01/2019 - 01/2019
3	Lenalidomide (CC 5013)FDA Link 01/2016 - 07/2014
3	1-(2-(dodecyloxy)ethyl)pyrrolidine hydrochloride (DEP)IBA 07/2014 - 04/2013
3	IntegrinsIBA 06/2014 - 07/2003
3	Surface Antigens (Surface Antigen)IBA 12/2012 - 01/2003
3	Cyclic NucleotidesIBA 09/2011 - 12/2008
3	Phosphoric Diester Hydrolases (Phosphodiesterases)IBA 09/2011 - 12/2008
3	VaccinesIBA 10/2007 - 08/2002
3	CD40 Ligand (CD40L)IBA 09/2005 - 03/2002
3	OligonucleotidesIBA 07/2003 - 09/2002
2	Chimeric Antigen ReceptorsIBA 03/2022 - 01/2015
2	pladienolide BIBA 01/2022 - 07/2015
2	FD 895IBA 01/2022 - 07/2015
2	ChromatinIBA 12/2021 - 01/2011
2	B-Cell Antigen Receptors (B Cell Antigen Receptors)IBA 01/2021 - 08/2013
2	Protein Serine-Threonine Kinases (Protein-Serine-Threonine Kinase)IBA 01/2020 - 04/2019
2	EnzymesIBA 11/2019 - 07/2003
2	rho GTP-Binding Proteins (rho GTP-Binding Protein)IBA 01/2019 - 06/2018
2	CortactinIBA 01/2019 - 01/2019
2	Rho Guanine Nucleotide Exchange FactorsIBA 01/2019 - 01/2019
2	RNA Splicing FactorsIBA 10/2018 - 03/2015
2	VimentinIBA 01/2018 - 06/2013
2	Long Noncoding RNAIBA 04/2017 - 01/2016
2	Immunoglobulin G (IgG)IBA 01/2017 - 02/2008
2	Peptides (Polypeptides)IBA 01/2017 - 09/2005
2	CXC ChemokinesIBA 01/2016 - 07/2014
2	Protein Isoforms (Isoforms)IBA 01/2016 - 12/2008

Therapy/Procedure

59	Therapeutics 10/2022 - 02/2002
16	Drug Therapy (Chemotherapy) 01/2022 - 03/2002
4	Ligation 04/2005 - 02/2002
3	Hematopoietic Stem Cell Transplantation 01/2020 - 01/2002
3	Immunotherapy 06/2012 - 01/2003